Skip to content
Get alerts
GovInfoNow
Lower risk Drug recall · FDA · Published January 5, 2023

Ascend Metoprolol Tablets Recall: Failed Dissolution Risk

Ascend Laboratories recalls 25mg Metoprolol Succinate Extended-Release Tablets due to failed dissolution specification. This may affect medication effectiveness. Check NDC 67877-590-01 and lot numbers 21143094-21143121.

Plain-English summary generated from official FDA data by GovInfoNow · Published by Carlos Caban · How we make summaries

🇺🇸 FDA recall #D-0169-2023DrugAscend Laboratories ›
Take action

Contact the company

Recalling firmAscend Laboratories, LLC339 Jefferson Rd Ste 101 · Parsippany, NJ 07054-3707
✎ GovInfoNow plain-language explainer

Ascend Laboratories is recalling 25mg Metoprolol Succinate Extended-Release Tablets because they failed to dissolve properly. This could mean the medication doesn't work as intended, which is dangerous for people taking it for heart conditions. Read more at govinfonow.com/recall/34012-ascend-metoprolol-tablets-recall-failed-dissolution-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/34012-ascend-metoprolol-tablets-recall-failed-dissolution-risk · Updated August 18, 2026 · FDA enforcement record: FDA #D-0169-2023

Cite this page

“Ascend Metoprolol Tablets Recall: Failed Dissolution Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34012-ascend-metoprolol-tablets-recall-failed-dissolution-risk. Based on FDA recall #D-0169-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0169-2023%22&limit=1).

The FDA announced on Jan. 5, 2023, that Ascend Laboratories voluntarily recalled Metoprolol Succinate Extended-Release Tablets due to failed dissolution specifications. The recall affects 49,632 bottles distributed nationwide and in Puerto Rico. GovInfoNow's records show the status is terminated.

How to tell if you have it

  • Brand: Ascend Laboratories
  • Product: Metoprolol Succinate Extended-Release Tablets, USP 25 mg, Rx Only, 100 Tablets per bottle
  • Manufacturer: Alkem Laboratories Ltd.
  • NDC: 67877-590-01
  • Lot codes: 21143094, 21143095, 21143119, 21143121, 21142389
  • Expiration date: 03/31/2023

The hazard

The tablets failed dissolution specifications. The FDA classified the recall as Class II.

Context

GovInfoNow's records show Ascend Laboratories has 35 other recalls on record since Nov. 2, 2016. Other recent recalls of similar products include Teva Metoprolol Succinate Tablets Recall (Jan. 29, 2026), Teva Metoprolol Succinate Extended-Release Tablets Recall (Jan. 29, 2026), and Teva Recalls Metoprolol Succinate 50 mg Due to Dissolution Failure (Jan. 29, 2026).

How to tell if you have this one

Check the product label for 'Metoprolol Succinate Extended-Release Tablets, USP 25 mg, Rx Only, 100 Tablets per bottle'. Look for lot numbers 21143094, 21143095, 21143119, 21143121, or 21142389 with expiration date 03/31/2023.

  • Brand
    Ascend Laboratories
  • Category
    Drug
FDA recall event · 3 products

All 3 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class II
  • Status
    Terminated
  • Distribution
    Nationwide and Puerto Rico
  • NDC
    67877-590-30, 67877-590-60, 67877-590-01, 67877-590-05, 67877-590-10, 67877-591-30, 67877-591-60, 67877-591-01, 67877-591-05, 67877-591-10, 67877-592-30, 67877-592-60, 67877-592-01, 67877-592-05, 67877-592-10, 67877-593-30, 67877-593-60, 67877-593-01, 67877-593-05, 67877-593-10
Recall numberProduct, codes & lotsQuantity
D-0169-2023Metoprolol Succinate Extended-Release Tablets, USP 25 mg, Rx Only, 100 Tablets per bottle, Manufactured by: Alkem Laboratories Ltd., Mumbai - 400 013, India, Distributed by: Ascend Laboratories, LLC, Parsippany NJ 07054, NDC 67877-590-01.; Lot #s: 21143094, 21143095, 21143119, 21143121, 21142389, Exp 03/31/2023.49,632 bottles
D-0170-2023Metoprolol Succinate Extended-Release Tablets, USP 50 mg, Rx Only, 100 Tablets per bottle, Manufactured by: Alkem Laboratories Ltd., Mumbai - 400 013, India, Distributed by: Ascend Laboratories, LLC, Parsippany NJ 07054, NDC 67877-591-01.; Lot #: 21142633, Exp 03/31/20236,336 bottles
D-0171-2023Metoprolol Succinate Extended-Release Tablets, USP 50 mg, Rx Only, 500 Tablets per bottle, Manufactured by: Alkem Laboratories Ltd., Mumbai - 400 013, India, Distributed by: Ascend Laboratories, LLC, Parsippany NJ 07054, NDC 67877-591-05.; Lot#: 21141321, 21141322, Exp 01/31/2023.2628 bottles
Based on the official FDA remedy

What to do — step by step

  1. Check Product Label

    Look for the lot numbers listed: 21143094, 21143095, 21143119, 21143121, or 21142389.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 19 months after the firm started it.

1. Firm started the recall: Jan 5, 202312. FDA classified it Class II: Jan 20, 202323. Published in FDA’s Enforcement Report: Feb 1, 202334. FDA terminated the recall: Aug 15, 2024420232024
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

From the GovInfoNow team · based on the FDA notice · How we make summaries

What should I do if I have this medication?

Check the product label for the lot numbers listed. If you have the affected lot numbers, contact your doctor or pharmacist for advice.

Similar recalls

Ascend Metoprolol Succinate 25mg Tablets: Failed Dissolution Risk
Ascend LaboratoriesAscend Minocycline Tablets Recall: Failed Dissolution Test Risk
Ascend LaboratoriesTeva Recalls Metoprolol Succinate 50 mg Due to Dissolution Failure
Teva PharmaceuticalsAscend Laboratories recalls Amlodipine/Olmesartan tablets with low drug content
Ascend LaboratoriesAmerican Health Packaging Recalls Metoclopramide Tablets Due to Foreign Drug Presence
American Health Packaging

Other Ascend Laboratories recalls

Ascend Laboratories, LLC recalls Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured
July 16, 2026Ascend Laboratories, LLC recalls Dabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories, Mumbai,
June 30, 2026Ascend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg, Rx Only, 30-count bottle, Manufactured by: Alkem Laboratories
May 5, 2026

Latest drug recalls

Teva Pharmaceuticals USA, Inc recalls Metoclopramide Tablets, USP, 5 mg, [100 or 500] Tablets per bottle, Rx Only, Manufactured for: Teva Pharmaceuticals,
Teva Pharmaceuticals · September 29, 2026Preferred Pharmaceuticals, Inc. recalls Lidocaine Ointment USP, 5% (Generic for Xylocaine), packaged in a 50 g jar, Rx only, Mfg: Taro Pharmaceuticals U.S.A.,
Preferred Pharmaceuticals · September 28, 2026SUN PHARMACEUTICAL INDUSTRIES INC recalls Tretinoin Cream USP, 0.05%, 45 g tube, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured by: Taro
Northstar Rx · September 25, 2026

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0169-2023 (January 5, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0169-2023 to see it in context.
  • Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA